Table 2.

The analysis results of the positive rate of rubella antibodies in each subgroup.

Subgroup	No. of studies	Rubella positive	Total	95%CI (%)	Heterogenity	χ2	P
					I2 (%)
Age (y)
<1	54	2696	7714	47.71 (41.25,54.16)	95.7	121.76	<0.001
1-4	69	13699	15809	85.26 (82.21,88.30)	93.9
5-9	70	8473	11124	78.34 (75.17,81.51)	94.2
10-14	33	4033	5759	74.00 (66.78,81.22)	98
15-19	59	9119	11947	76.47 (71.68,81.27)	96.2
20-34	32	6941	8586	81.43 (78.54,84.32)	88.8
35-49	20	1614	2045	82.55 (78.67,86.44)	83.2
≥50	18	1287	1572	85.43 (81.01,89.85)	89.5
Gender
Male	46	20689	25912	78.28 (74.95,81.62)	97.7	0.15	0.7
Female	46	19490	24228	79.18 (76.10,82.26)	97.1
District
Urban	15	7606	9162	79.50 (73.49,85.50)	95.6	0.1	0.757
Rural	15	9367	11420	78.12 (71.75,84.49)	95.8
Registration
permanent population	13	8581	10868	79.45 (73.25,85.64)	98.7	0.24	0.63
migrant population	13	3245	4115	77.52 (72.87,82.17)	90.2
Regions of China
East China	24	28981	38673	77.68 (73.88,81.48)	98.8	6.62	0.358
Southwest	18	14131	18244	74.01 (68.75,79.27)	98.9
Northwest	14	5444	6593	80.40 (74.76,86.03)	95.2
South China	17	7790	9927	76.53 (71.32,81.73)	96.3
North China	7	2082	2804	77.16 (71.79,82.54)	91.3
Central China	12	14700	19515	79.13 (72.88,85.38)	99.4
Northeast	4	6181	7598	82.52 (77.55,87.48)	96.4
Immunization history
0dose	21	1744	3002	58.23 (47.20,69.25)	98.6	15.44	0.002
1dose	25	3068	3945	77.46 (73.01,81.92)	90.6
≥2dose	24	7922	9994	80.45 (76.36,84.55)	96.3
Unknown	12	3698	4723	80.61 (77.23,84.00)	82.8
The year of study
2001-2008	9	3709	5191	70.42 (62.17,78.68)	97.3	3.26	0.35
2009-2013	28	14808	18652	78.17 (74.28,82.25)	97.1
2014-2018	47	37413	48737	75.15 (71.79,78.51)	98.7
2019-2022	21	14581	20077	75.21 (70.38,80.04)	99.1